- Thinly traded nano cap Genetic Technologies (NASDAQ:GENE +50.2%) zooms up on a massive 35x surge in volume. Surprisingly, no particular news accounts for the action.
- On Monday, the company's U.S. subsidiary issued a statement about the use of BREVAGenplus to assist physicians in deciding which of their female patients who are at average risk of breast cancer are suitable for mammograms. According to the company, there is a certain amount of uncertainty regarding the frequency of breast cancer screening in light of the recent changes in guidelines from the American Cancer Society. The new guidance recommends average risk women undergo their first mammogram at age 45 instead of 40 and women over age 55 undergo screening every two years instead of every year. It says BRAVAGenplus, its genetic breast cancer risk assessment test, can help doctors address the ambiguity since some women aged 40 - 44 may be candidates for a mammogram and certain women over age 55 may need to continue with annual screenings.